Thursday, November 12, 2026

Zoomex Wins US, Canada Crypto Licenses as Exchanges Race for Regulatory Access

Zoomex secured Money Services Business licenses in the United States and Canada, joining exchanges worldwide pursuing regulatory approval to access institutional capital. The dual licensing requires anti-money laundering controls and transaction monitoring aligned with traditional banking standards. The move reflects industry-wide recognition that compliance has become essential for institutional crypto adoption.

LM Salvado
LM Salvado

April 16, 2026

Zoomex Wins US, Canada Crypto Licenses as Exchanges Race for Regulatory Access
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Zoomex secured Money Services Business (MSB) licenses in the United States and Canada, joining exchanges worldwide pursuing regulatory approval to access institutional capital.1

The dual-jurisdiction licensing requires anti-money laundering controls, customer identification procedures, and transaction monitoring systems aligned with traditional banking standards.1 Zoomex also obtained licensing from Mantle, though operational details remain limited.1

The regulatory push extends beyond North America. European exchanges operate under MiCA regulations, while Asian platforms navigate fragmented frameworks from Singapore's Payment Services Act to Japan's strict licensing regime. The US-Canada MSB approach creates standardized oversight comparable to money transmitters and payment processors.

Traditional financial institutions are increasing crypto infrastructure investments. Regulatory clarity in major markets reduces operational risk for banks and asset managers considering crypto trading services. Asset managers require exchanges to meet specific regulatory thresholds before directing client capital to digital asset platforms.

MSB status addresses institutional concerns about counterparty risk and compliance liability. For retail investors globally, regulated exchange status provides consumer protections and oversight through financial reporting, capital requirements, and operational transparency that unlicensed platforms lack.

The compliance trend marks a strategic shift from crypto's historically libertarian stance on financial regulation. Exchanges now view regulatory costs and operational restrictions as acceptable trade-offs for institutional capital inflows.

Traditional finance integration with crypto platforms will likely accelerate through 2026 as more exchanges complete regulatory processes in key jurisdictions. The infrastructure gap between legacy banking systems and crypto markets continues to narrow as exchanges worldwide adopt conventional financial controls.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com